Drug Trial Radar · NCT06850922
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
388
Actual
Start
Jun 22, 2022
Primary completion
May 19, 2026
Study completion Jun 19, 2026
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Feb 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1-4) and Phase II (Part 5). Phase I investigated the safety of RO7446603 following a single and multiple intravitreal (IVT) doses as monotherapy or co-administered with IVT aflibercept or IVT faricimab (in separate injections). Phase II will investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of two dose levels of RO7446603 in combination with faricimab, with the two drugs co-mixed and administered as a single IVT injection, compared to faricimab alone. The first participant was enrolled in the Phase I segment on June 22, 2022. Phase I has been completed.
Conditions
- Diabetic Macular Edema
Interventions
RO7446603Drug
Participants will receive RO7446603 as an IVT injection per the schedule described in the treatment arms.
AfliberceptDrug
Participants will receive aflibercept as an IVT injection per the schedule described in the treatment arm.
FaricimabDrug
Participants will receive faricimab as an IVT injection per the schedule described in the treatment arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts 1-5: Percentage of Participants With Adverse Events (AEs)Time frame: From study start through end of study (Up to approximately 58 months)
- Parts 1-5: Percentage of Participants With Ocular AEsTime frame: From study start through end of study (Up to approximately 58 months)
- Part 1: Change in Best Corrected Visual Acuity (BCVA) Over TimeTime frame: From Baseline up to Week 16
- Parts 2-4: Change in BCVA Over TimeTime frame: From Baseline up to Week 28
- Part 5: Change From Baseline in BCVA Averaged Over Weeks 52 and 56Time frame: From Baseline up to Week 56
Locations
77 sites in 3 countries. Site status is shown where the registry gives one.
Arizona Retina and Vitreous Consultants
Phoenix, Arizona
Associated Retinal Consultants PC
Phoenix, Arizona
Retinal Research Institute, LLC
Phoenix, Arizona
Retina Partners of Northwest Arkansas, PLLC
Springdale, Arkansas
Retinal Diagnostic Center
Campbell, California
Retina Consultants of Orange County
Fullerton, California
Retinal Consultants Medical Group
Modesto, California
Northern California Retina-Vitreous Associates
Mountain View, California
Retinal Consultants Medical Group
Sacramento, California
University of California San Francisco
San Francisco, California
Macula Retina Vitreous Research Institute
Torrance, California
Bay Area Retina Associates;Study Department
Walnut Creek, California
University of Colorado - Eye Center - PPDS
Aurora, Colorado
Retina Consultants of Southern Colorado PC
Colorado Springs, Colorado
Retina Specialists of Colorado
Denver, Colorado
Advanced Vision Research Institute
Longmont, Colorado
Retina Group of New England
Waterford, Connecticut
National Ophthalmic Research Institute
Fort Myers, Florida
Florida Retina Institute
Jacksonville, Florida
Retina Associates of Florida;Retina Associates of Florida
Tampa, Florida
Southeast Retina Center
Augusta, Georgia
Georgia Retina PC
Marietta, Georgia
Retina Consultants of Hawaii
‘Aiea, Hawaii
Illinois Eye and Ear Infirmary
Chicago, Illinois
University Retina and Macula Associates, PC
Oak Forest, Illinois
Raj K. Maturi, MD PC
Indianapolis, Indiana
The Retina Care Center
Baltimore, Maryland
Johns Hopkins Hospital
Baltimore, Maryland
Retina Group of Washington
Chevy Chase, Maryland
Cumberland Valley Retina Consultants
Hagerstown, Maryland
Chesapeake Retina Centers - Waldorf
Waldorf, Maryland
Associated Retinal Consultants - Royal Oak
Royal Oak, Michigan
Retina Consultants Minnesota
Saint Louis Park, Minnesota
Long Island Vitreoretinal Consultants;Opthalmology
Hauppauge, New York
Retina Vitreous Surgeons of CNY PC
Liverpool, New York
Opthalmic Consultants of LI
Lynbrook, New York
Western Carolina Retinal Associate PA
Asheville, North Carolina
North Carolina Retina Associates
Cary, North Carolina
Duke University Medical Center
Durham, North Carolina
Graystone Eye-Hickory
Hickory, North Carolina
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.